Author(s):
Atanu Bhattacharjee, Nongmaithem Randhoni Chanu, Kunal Bhattacharya
Email(s):
kunal22101994@gmail.com
DOI:
10.52711/0974-360X.2022.00478 
Address:
Atanu Bhattacharjee1, Nongmaithem Randhoni Chanu2, Kunal Bhattacharya3,4*
1Royal School of Pharmacy, Royal Global University, Guwahati, Assam – 781035.
2Faculty of Pharmaceutical Science, Assam Downtown University, Assam – 781026.
3NETES Institute of Pharmaceutical Science, Mirza, Kamrup, Assam – 781125.
4Pratiksha Institute of Pharmaceutical Sciences, Guwahati, Assam-781026.
*Corresponding Author
Published In:
Volume - 15,
Issue - 6,
Year - 2022
ABSTRACT:
The prevalence of the Novel Coronavirus Covid-19 pandemic is growing worldwide and the third phase of this deadly flu has already been started across the globe. COVID-19 has already been emerged as one of the most devastating epidemics throughout the world with the highest rate of mortality and has become the most important health challenge in developed and developing countries. This paper totals and solidifies the study of disease transmission, clinical signs, finding, medications and counteractions of this new sort of COVID-19. Data were collected from the articles published in various electronic databases such as Elsevier, Science Direct, Scopus, PubMed between 2010 and 2020. Existing literature, news and media, a various statutory body of the Health Ministry of various countries, World Health Organization (WHO) has said that there is no particular medicine to prevent or treat coronavirus disease till date. Few antiviral drugs combination of lopinavir and ritonavir, antimalarial drugs like chloroquine and hydroxychloroquine are widely used as an effective medicine to treat COVID-19 to date. A search vaccine is in progress up to the clinical trial stage in many countries including China, the USA and India. Need of the hour is high-quality clinical data from different geographic areas to develop the vaccine and safe drugs.
Cite this article:
Atanu Bhattacharjee, Nongmaithem Randhoni Chanu, Kunal Bhattacharya. COVID-19 Pandemic: A Pragmatic plan for Therapeutic Intervention. Research Journal of Pharmacy and Technology. 2022; 15(6):2862-8. doi: 10.52711/0974-360X.2022.00478
Cite(Electronic):
Atanu Bhattacharjee, Nongmaithem Randhoni Chanu, Kunal Bhattacharya. COVID-19 Pandemic: A Pragmatic plan for Therapeutic Intervention. Research Journal of Pharmacy and Technology. 2022; 15(6):2862-8. doi: 10.52711/0974-360X.2022.00478 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2022-15-6-82
REFERENCES:
1. Patil VK. Shaikh AZ. Corona (Covid - 19). Asian Journal of Pharmaceutical Research. 2020; 10(4): 275-285. doi.org/10.5958/2231-5691.2020.00040.4
2. Rokade M. Khandagale P. Coronavirus Disease: A Review of a New Threat to Public Health. Asian Journal of Pharmaceutical Research. 2020; 10(3):241-244. doi.org/10.5958/2231-5691.2020.00042.8
3. Huang C. Yeming W. Xingwang L. Lilli R. Jianping Z. Yi H. Li Z et al. Clinical Features of Patients. Infected with 2019 Novel Coronavirus in Wuhan, China. The Lancet. 2020; 395(10223):497–506. doi.org/10.1016/S0140-6736(20)30183-5
4. Chen N. Min Z. Xuan D. Jieming Q. Fengyun G. Yang H. Yang Q et al. Epidemiological and Clinical Characteristics of 99 Cases of 2019 Novel Coronavirus Pneumonia in Wuhan, China: A Descriptive Study. The Lancet. 2020; 395(10223):507–513. doi.org/10.1016/S0140-6736(20)30211-7
5. Chan JF. Kelvin KW. Honglin C. Kwok YY. Cross-Species Transmission and Emergence of Novel Viruses from Birds. Current Opinion in Virology. 2015; 10:63–69. doi.org/10.1016/j.coviro.2015.01.006
6. Naresh BV. A Review of the 2019 Novel Coronavirus (COVID-19) Pandemic. Asian Journal of Pharmaceutical Research. 2020; 10(3):233-238. doi.org/10.5958/2231-5691.2020.00040.4
7. Farhana N. Ansari T. Ansari M. Sars-CoV-2leader-RNA-primed Transcription and RNA-Splicing prevention, control and Treatment. Asian Journal of Research in Chemistry. 2020; 13(4):291-298. doi.org/10.5958/0974-4150.2020.00057.7
8. Wu A. Yousong P. Baoying H. Xiao D. Xianyue W. Peihua N. Jing M et al. Genome Composition and Divergence of the Novel Coronavirus (2019-NCoV) Originating in China. Cell Host Microbe. 2020; 27(3):325–328. doi.org/10.1016/j.chom.2020.02.001
9. Lupia T. Scabini S. Pinna SM. Perri GD. Rosa FG. Corcione S. 2019 novel coronavirus (2019-nCoV) outbreak:A new challenge. Journal of Global Antimicrobial Resistance. 2020; 21:22–27. doi.org/10.1016/j.jgar.2020.02.021
10. Leila M. Sorayya G. Genotype and phenotype of COVID-19: Their roles in pathogenesis. Journal of Microbiology Immunology and Infection. 2021; 54(2):159-163. doi.org/ 10.1016/j.jmii.2020.03.022
11. Li H, Shang ML, Xiao HY, Shi LT. Chao KT. Coronavirus disease 2019 (COVID-19): current status and future perspectives. International Journal of Antimicrobial Agents. 2020; 55(5):105951. doi.org/10.1016/j.ijantimicag.2020.105951
12. Kim JM. Yoon SC. Hye JJ. Nam JL. Mi SK. Sang HW. Sehee P et al. Identification of Coronavirus Isolated from a Patient in Korea with COVID-19. Osong Public Health and Research Perspectives. 2020; 11(1):3–7. doi.org/10.24171/j.phrp.2020.11.1.02
13. Markus H. Hannah KW. Simon S. Nadine K. Tanja H. Sandra E. Tobias SS et al. Stefan P. The Novel Coronavirus 2019 (2019-NCoV) Uses the SARS-Coronavirus Receptor ACE2 and the Cellular Protease TMPRSS2 for Entry into Target Cells. Cell. 2020; 181(2):271-280. doi.org/10.1016/j.cell.2020.02.052
14. Daniel W. Nianshuang W. Kizzmekia SC. Jory AG. Ching LH. Olubukola A. Barney SG et al. Cryo-EM Structure of the 2019-NCoV Spike in the prefusion conformation. Science. 2020; 367(6483):1260–1263. doi.org/ 10.1126/science.abb2507
15. Ky B. Douglas LM. Covid-19 clinical trials: a primer for the cardiovascular and cardio-oncology communities. JACC: Basic to Translational Science. 2020; 5(5):501–517. doi.org/10.1016/j.jacbts.2020.04.003
16. Ying L. Albert AG. Annelies WS. Joacim R. The reproductive number of covid-19 is higher compared to SARS coronavirus. Journal of Travel Medicine. 2020; 27(2): 1–4. doi.org/10.1093/jtm/taaa021
17. Wu JT. Kathy L. Gabriel ML. Now casting and forecasting the potential domestic and international spread of the 2019- NCoV outbreak originating in Wuhan, China: a modelling study. The Lancet. 2020; 395(10225): 689– 697. doi.org/10.1016/S0140-6736(20)30260-9
18. Majumder MS. Kenneth DM. Early Transmissibility Assessment of a Novel Coronavirus in Wuhan, China. SSRN Electronic Journal. 2020 (In Press). doi.org/10.2139/ssrn.3524675
19. Remais J. Modelling environmentally-mediated infectious diseases of humans: transmission dynamics of schistosomiasis in China.” Advances in Experimental Medicine and Biology. 2010; 673:79–98. doi.org/10.1007/978-1-4419-6064-1_6
20. Guan WJ. Ni Z. Hu Y. Liang WH. Ou CQ. He JX. Liu L et al. Clinical characteristics of 2019 novel coronavirus infection in China. New England Journal of Medicine. 2020; 3154(01):18–27. doi.org/10.1056/NEJMoa2002032
21. Wu Z. Jennifer MM. Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in china: summary of a report of 72314 cases from the Chinese center for disease control and prevention. Journal of the American Medical Association. 2020; 323(13):1239–1242. doi.org/10.1001/jama.2020.2648
22. Patil P. Jain R. Theoretical Study and treatment of Novel COVID-19. Research Journal of Pharmacology and Pharmacodynamics. 2020; 12(2): 71-72. doi.org/10.5958/2321-5836.2020.00014.2
23. Choi SH. Kim HW. Kang JM. Kim DH. Cho EY. Epidemiology and clinical features of coronavirus disease 2019 in children. CEP. 2020; 63(4):125-132. doi.org/10.3345/cep.2020.00535
24. Barreto ML. Maria GT. Eduardo HC. Infectious Diseases Epidemiology. Journal of Epidemiology and Community Health. 2006; 60(3):192–195. doi.org/10.1136/jech.2003.011593
25. Wang W. Jianming T. Fangqiang W. Updated understanding of the outbreak of 2019 Novel Coronavirus (2019-NCoV) in Wuhan, China. Journal of Medical Virology. 2020; 92(4):441–447. doi.org/10.1002/jmv.25689
26. Gade A. Sawant R. Parkar S. Prajakta K. SARS-Cov-2 The Beta Genome Coronavirus: A Brief Overview, Pathogenesis and Treatment. Asian Journal of Research in Pharmaceutical Sciences. 2020; 10(4):299-310. doi.org/10.5958/2231-5659.2020.00052.1
27. Xia J. Jianping T. Mengyun L. Ye S. Dongyu G. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. Journal of Medical Virology. 2020; 92(6): 589–594. doi.org/10.1002/jmv.25725
28. Long C. Huaxiang X. Qinglin S. Xianghai Z. Bing F. Chuanhong W. Bingliang Z et al. Diagnosis of the Coronavirus disease (COVID-19): RRT-PCR or CT. European Journal of Radiology. 2020; 126(108961): 1-6. doi.org/10.1016/j.ejrad.2020.108961
29. Michelle LH. Chas D. Scott L. Kathy HL. John W. Hollianne B. Christopher S et al. First case of 2019 novel coronavirus in the United States. New England Journal of Medicine. 2020; 382(10): 929–936. doi.org/10.1056/nejmoa2001191
30. Gupta R. The Management of Coronavius Pandemic 2019-2020. Asian Journal of Research in Pharmaceutical Sciences. 2020; 10(4):327-330. doi.org/10.5958/2231-5691.2020.00056.8
31. Viveiros R. Sandro G. Wilson CS. Clinical trials on drug repositioning for Covid-19 treatment. Revista Panamericana de Salud Publica/Pan American Journal of Public Health 2020; 44:1–7. doi.org/10.26633%2FRPSP.2020.40
32. Jain M. Barhate S. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19: A Review. Asian Journal of Research in Pharmaceutical Sciences. 2021; 11(1):8. doi.org/10.5958/2231-5691.2021.00008.3
33. • 33. Sheila M. Vidya B. Review of the impact Covid-19 has on the Psychosocial factors affecting Well Being. Research Journal of Pharmacy and Technology. 2021; 14(6):3404-3408. doi.org/10.52711/0974-360X.2021.00592
34. Nicola P. Sussana E. Chloroquine or hydroxychloroquine for prophylaxis of Covid-19. The Lancet. 2020; 20(10):1118. doi.org/10.1016/S1473-3099(20)30296-6
35. Wang L. Yiru W. Dawei Y. Qingquan L. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. International Journal of Antimicrobial Agents 2020; 55(6):105948. doi.org/10.1016/j.ijantimicag.2020.105948
36. Kumar V. Young SJ. Po HL. Anti-SARS coronavirus agents: a patent review (2008-Present). Expert Opinion on Therapeutic Patents. 2013; 23(10):1337–1348. doi.org/10.1517/13543776.2013.823159
37. Yadav AR, Shrinivas KM. A Novel Approach for Treatment of COVID-19 with Convalescent Plasma. Research Journal of Pharmaceutical Dosage Forms and Technology. 2020;12(3):227-230. doi.org/10.5958/0975-4377.2020.00037.3
38. Mair J. Maria SC. Kenneth B. Paul C. Fu MK. Wei SL. Sophi M et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. Journal of Infectious Diseases.2015; 211(1):80–90. doi.org/10.1093/infdis/jiu396
39. Lai ST. Treatment of Severe Acute Respiratory Syndrome. European Journal of Clinical Microbiology and Infectious Diseases, 2005; 24(9):583–591. doi.org/10.1007/s10096-005-0004-z
40. Tripathi D. Guohua Y. Ramakrishna V. COVID-19: An Update on Vaccine Development. Indian Journal of Rheumatology 2020;15(2):70–72. doi.org/10.4103/0973-3698.285394
41. Khan TM. Preventive and Control Measures of COVID-19 Patients: A Review. Bangladesh Journal of Infectious Diseases. 2020; 7(1):41–44. doi.org/10.3329/bjid.v7i0.46800
42. Naina M. Pakkir M. Adjuvant Therapies of COVID-19 - A Literature Review. Coronaviruses. 2021; 2: 1-10. doi.org/10.2174/2666796702666210121144902
43. Bhattacharya K. Chanu NR. Bhattacharjee A. Bordoloi R. Sahariah BJ. Talukdar A. Kalita R. Quercetin for the Experimental Treatment of Covid-19. Handbook of Research on Knowledge and Organization Systems in Library and Information Science. 2021:69-87. doi.org/10.4018/978-1-7998-7258-0.ch004